Clinical Trial Update: Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of iodine-131 monoclonal antibody 3F8 in CNS and leptomeningeal cancers completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain and Central Nervous System Tumors
• Leptomeningeal Cancer

Drugs mentioned

• iodine-131 monoclonal antibody 3F8 (iodine-131 monoclonal antibody 3F8)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Brain and Central Nervous System Tumors, Intraocular Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2024-04-04